Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of October 28, 2026, ACAD trades at $20.27 with a market cap of $3.48B and a P/E ratio of 8.97. ACAD moved +0.74% today. Year to date, ACAD is -22.71%; over the trailing twelve months it is -10.17%. Its 52-week range spans $13.40 to $30.96. Analyst consensus is buy with an average price target of $31.43. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
15 analysts cover ACAD: 0 strong buy, 10 buy, 5 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $31.43.
| Metric | Value |
|---|---|
| Price | $20.27 |
| Market Cap | $3.48B |
| P/E Ratio | 8.97 |
| EPS | $2.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.96 |
| 52-Week Low | $13.40 |
| Volume | 977.06K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.14B |
| Net Income | $380.48M |
| Gross Margin | 91.13% |
15 analysts cover ACAD: 0 strong buy, 10 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $31.43.